Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ella Zomer

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
Journal of Clinical Lipidology|September 30, 2020
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysisKanila Perera, Ning Kam, Zanfina Ademi, et al.
Tobacco Control|July 18, 2018
Productivity burden of smoking in Australia: a life table modelling studyAlice J Owen, Salsabil B Maulida, Ella Zomer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 16, 2021
It doesn't stop at validation: patient reported outcome measures require ongoing and iterative developmentCatriona Parker, Andrew Wei, Danny Liew, et al.
Heart, Lung & Circulation|April 19, 2020
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian PerspectiveKen Lee Chin, Ella Zomer, Bing H Wang, et al.
Vaccine|July 15, 2019
Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescentsSi Si, Ella Zomer, Samantha Fletcher, et al.
Pharmacoeconomics|August 14, 2020
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness AnalysisNing Kam, Kanila Perera, Ella Zomer, et al.
BMJ Open|August 1, 2022
Estimating the economic impact of acute coronary syndrome in New Zealand over time (ANZACS-QI 64): a national registry-based cost burden studyPeter Lee, A J Kerr, Yannan Jiang, et al.
European Journal of Preventive Cardiology|July 23, 2021
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reductionZanfina Ademi, Richard Ofori-Asenso, Ella Zomer, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 18, 2010
Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the 'old' versus the 'new' Framingham equationElla Zomer, Alice Owen, Dianna J Magliano, et al.
Headache|October 7, 2020
The Health and Productivity Burden of Migraines in AustraliaSusan Tu, Danny Liew, Zanfina Ademi, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
Journal of Clinical Lipidology|September 30, 2020
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysisKanila Perera, Ning Kam, Zanfina Ademi, et al.
Tobacco Control|July 18, 2018
Productivity burden of smoking in Australia: a life table modelling studyAlice J Owen, Salsabil B Maulida, Ella Zomer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 16, 2021
It doesn't stop at validation: patient reported outcome measures require ongoing and iterative developmentCatriona Parker, Andrew Wei, Danny Liew, et al.
Heart, Lung & Circulation|April 19, 2020
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian PerspectiveKen Lee Chin, Ella Zomer, Bing H Wang, et al.
Vaccine|July 15, 2019
Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescentsSi Si, Ella Zomer, Samantha Fletcher, et al.
Pharmacoeconomics|August 14, 2020
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness AnalysisNing Kam, Kanila Perera, Ella Zomer, et al.
BMJ Open|August 1, 2022
Estimating the economic impact of acute coronary syndrome in New Zealand over time (ANZACS-QI 64): a national registry-based cost burden studyPeter Lee, A J Kerr, Yannan Jiang, et al.
European Journal of Preventive Cardiology|July 23, 2021
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reductionZanfina Ademi, Richard Ofori-Asenso, Ella Zomer, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|May 18, 2010
Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the 'old' versus the 'new' Framingham equationElla Zomer, Alice Owen, Dianna J Magliano, et al.
Headache|October 7, 2020
The Health and Productivity Burden of Migraines in AustraliaSusan Tu, Danny Liew, Zanfina Ademi, et al.
Pageof 12